*ST Jiyou announced plans to acquire a 50.76% stake in Jiangsu HuiJu Pharmaceutical Co., Ltd. for 1.006 billion yuan in cash, which is expected to constitute a major asset restructuring and a related-party transaction. HuiJu Pharma's total assets, net assets, and operating revenue for 2025 were 1.39 billion yuan, 1.006 billion yuan, and 585 million yuan, respectively, accounting for 101.86%, 79.46%, and 342.11% of *ST Jiyou's corresponding metrics. After the transaction, *ST Jiyou's 2025 operating revenue will increase from 171 million yuan to 757 million yuan, a change of 342.11%, which is expected to help the company lift its delisting risk warning. Meanwhile, controlling shareholder Xu Shanshui plans to transfer 5.0526% of shares to HuiJu Pharma shareholders Huang Hua and Bi Weiguo at 9.72 yuan per share, with total transfer consideration of 515 million yuan, thereby constituting a related-party transaction. The counterparty has committed that HuiJu Pharma's net profit after deducting non-recurring items and excluding the impact of share-based payment expenses will be no less than 134 million yuan, 168 million yuan, and 221 million yuan for 2026, 2027, and 2028, respectively.
Anhui Genuine New Materials Co LtdHuiJu Pharma is the target of a 1.006 billion yuan acquisition, with profit commitments indicating strong future performance